X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs SANOFI INDIA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. SANOFI INDIA WOCKHARDT LTD./
SANOFI INDIA
 
P/E (TTM) x -18.3 37.3 - View Chart
P/BV x 1.9 7.0 27.6% View Chart
Dividend Yield % 0.0 0.5 0.4%  

Financials

 WOCKHARDT LTD.   SANOFI INDIA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
SANOFI INDIA
Dec-17
WOCKHARDT LTD./
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,0124,945 20.5%   
Low Rs5323,901 13.6%   
Sales per share (Unadj.) Rs355.91,081.8 32.9%  
Earnings per share (Unadj.) Rs-60.3141.6 -42.6%  
Cash flow per share (Unadj.) Rs-46.8185.9 -25.1%  
Dividends per share (Unadj.) Rs0.0133.00 0.0%  
Dividend yield (eoy) %00.7 0.2%  
Book value per share (Unadj.) Rs257.8868.8 29.7%  
Shares outstanding (eoy) m110.6323.03 480.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.24.1 53.0%   
Avg P/E ratio x-12.831.2 -41.0%  
P/CF ratio (eoy) x-16.523.8 -69.4%  
Price / Book Value ratio x3.05.1 58.8%  
Dividend payout %023.3 -0.1%   
Avg Mkt Cap Rs m85,379101,862 83.8%   
No. of employees `0006.33.2 193.1%   
Total wages/salary Rs m9,3713,685 254.3%   
Avg. sales/employee Rs Th6,295.07,691.9 81.8%   
Avg. wages/employee Rs Th1,498.31,137.7 131.7%   
Avg. net profit/employee Rs Th-1,066.31,006.5 -105.9%   
INCOME DATA
Net Sales Rs m39,36924,914 158.0%  
Other income Rs m1,202807 149.0%   
Total revenues Rs m40,57125,721 157.7%   
Gross profit Rs m185,372 0.3%  
Depreciation Rs m1,4951,022 146.3%   
Interest Rs m2,55511 23,226.4%   
Profit before tax Rs m-2,8305,146 -55.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2571,886 13.6%   
Profit after tax Rs m-6,6693,260 -204.6%  
Gross profit margin %021.6 0.2%  
Effective tax rate %-9.136.6 -24.8%   
Net profit margin %-16.913.1 -129.4%  
BALANCE SHEET DATA
Current assets Rs m33,79614,432 234.2%   
Current liabilities Rs m26,9176,010 447.9%   
Net working cap to sales %17.533.8 51.7%  
Current ratio x1.32.4 52.3%  
Inventory Days Days7961 130.3%  
Debtors Days Days8928 313.3%  
Net fixed assets Rs m39,6647,991 496.4%   
Share capital Rs m553230 240.2%   
"Free" reserves Rs m27,96819,778 141.4%   
Net worth Rs m28,52220,008 142.5%   
Long term debt Rs m21,7310-   
Total assets Rs m81,62027,770 293.9%  
Interest coverage x-0.1468.8 -0.0%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.50.9 53.8%   
Return on assets %-5.011.8 -42.8%  
Return on equity %-23.416.3 -143.5%  
Return on capital %-7.725.8 -29.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,8076,306 155.5%   
Fx outflow Rs m1,7895,257 34.0%   
Net fx Rs m8,0191,049 764.4%   
CASH FLOW
From Operations Rs m6844,351 15.7%  
From Investments Rs m6,302-787 -800.8%  
From Financial Activity Rs m-7,695-1,884 408.4%  
Net Cashflow Rs m-6641,680 -39.5%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 2.3 14.4 16.0%  
FIIs % 7.7 14.6 52.7%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   67,757 15,184 446.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open on a Positive Note; Realty & Auto Stocks Lead(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.2% while the Hang Seng is up 1.6%.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Dec 12, 2018 11:17 AM

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - STRIDES PHARMA SCIENCE COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS